Abstract Number: 0421 • ACR Convergence 2021
Negative vs. Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis, a Case-control Study
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) negative granulomatosis with polyangiitis (GPA) is a challenging diagnosis. There is paucity of literature regarding the clinical course of ANCA-negative…Abstract Number: 0525 • ACR Convergence 2021
STEAP3, FZD2 and EGFLAM Are Novel Genetic Risk Loci for Granulomatosis with Polyangitis: A Genome Wide Association Study from UK Biobank
Background/Purpose: Granulomatosis with Polyangitis (GPA) is a systemic ANCA associated small vessel vasculitis. Prior genetic studies demonstrated a strong association of HLA Class II region…Abstract Number: 0422 • ACR Convergence 2021
Cancer in Patients with ANCA-associated Vasculitis: Which Came First, the Chicken or the Egg?
Background/Purpose: Many studies linking vasculitis to the development of malignancy based on chronic inflammation, cytotoxicity, emergence of vasculitis as a paraneoplastic disease. Even previous studies…Abstract Number: 0533 • ACR Convergence 2021
Identification of a Novel Susceptibility Locus for Small Vessel Vasculitis with Autoantibodies Against Myeloperoxidase
Background/Purpose: ANCA-associated vasculitides (AAV) are rare but aggressive autoimmune disorders. The pathogenesis of the disorders is complex and still poorly understood; only a few genetic…Abstract Number: 0423 • ACR Convergence 2021
Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV), however it is not clear whether activation of complement occurs…Abstract Number: 0952 • ACR Convergence 2021
Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry
Background/Purpose: Patients with primary systemic vasculitis (PSV) and polymyalgia rheumatica (PMR) may be at high risk for poor COVID-19 outcomes due to the treatments used,…Abstract Number: 0425 • ACR Convergence 2021
Diagnostic Accuracy of Muscle MRI for Muscular Vasculitis in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Pilot Study
Background/Purpose: Histopathologic confirmation is the golden standard for diagnosis of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), but sometimes can be difficult because of its invasion (e.g.…Abstract Number: 0953 • ACR Convergence 2021
An International Delphi Exercise to Identify Items of Importance for Measuring Response to Treatment for ANCA-associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by fluctuating levels of disease activity. Randomized controlled trials (RCTs) in AAV have used multiple instruments to define active…Abstract Number: 0426 • ACR Convergence 2021
Ocular Manifestations of ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitides (AAV) are multisystem diseases that can have multiple ophthalmic manifestations. Although there are some data on ocular disease in granulomatosis with polyangiitis…Abstract Number: 0954 • ACR Convergence 2021
The Association of Rituximab- vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis
Background/Purpose: The RAVE trial established the non-inferiority of rituximab (RTX) vs cyclophosphamide (CYC) for remission induction of ANCA-Associated Vasculitis (AAV). Patients in RAVE were followed…Abstract Number: 0427 • ACR Convergence 2021
Increased Risk of Severe Infections and Mortality in Patients with Newly Diagnosed Anti-neutrophil Cytoplasmic Antibody–associated Vasculitis: A Population-based Study
Background/Purpose: Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are a group of multisystem inflammatory diseases of the small blood vessels. Infections are serious complications in AAV…Abstract Number: 0955 • ACR Convergence 2021
The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was evaluated in ANCA-associated vasculitis (AAV). Efficacy and safety results were reported previously. Health-related quality of life (HRQoL)…Abstract Number: 0428 • ACR Convergence 2021
ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with rheumatoid arthritis (RA) has been reported rarely, and, studies have found ANCA positivity in RA. The…Abstract Number: 1054 • ACR Convergence 2021
Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study
Background/Purpose: Patients with rheumatic diseases (RMD) face an increased cardiovascular (CV) mortality compared to the general population. Still, risk stratification based on traditional cardiovascular risk…Abstract Number: 0429 • ACR Convergence 2021
Causes and Characteristics of Death in ANCA-Associated Vasculitis – A Large, Real-Life, Contemporary Cohort Analysis
Background/Purpose: Despite improvements, patients with ANCA-associated vasculitis (AAV) have a higher risk of death than the general population. Contemporary treatment is associated with high remission…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 19
- Next Page »